Dr. Schumacher is a preeminent scientist in the field of T cell immunity. In addition to his role as the Chief Scientific Officer of Kite Pharma EU, Dr. Schumacher is Principal Investigator at The Netherlands Cancer Institute, where he also serves as Deputy Director. His lab focuses on the development of novel technologies with which T cell responses can be measured or manipulated, and the subsequent use of these technologies to dissect tumor-specific T cell immunity in clinically effective cancer immunotherapies. Dr. Schumacher co-founded T Cell Factory B.V. which was acquired by Kite Pharma in 2015 and focused on discovery and development of tumor-specific TCRs for broad use in cancer treatment based on its TCR-GENErator™ platform. Previously, he held postdoctoral positions at the MIT Center for Cancer Research and The Whitehead Institute for Biomedical Research. Schumacher is also member of the Cancer Research Institute Council, is SU2C-CRI Immunotherapy Dream Team member, and Professor of Immunotechnology at Leiden University. Among Dr. Schumacher’s numerous awards are the Amsterdam Inventor Award, Queen Wilhelmina Research Award, San Salvatore Award, Pioneer Award, and Meyenburg Cancer Research Award. He earned his M.Sc. in Medical Biology from the University of Amsterdam and his Ph.D. in Biochemistry from the Free University of Amsterdam and conducted research from 1988 to 1992 at The Netherlands Cancer Institute where he described the interactions of MHC class I molecules with antigenic peptides in the laboratory of Hidde Plough.